Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Iluvien Articles

pSivida and Alimera's Iluvien debuts in Germany; New data on Novartis' Lucentis

8 May 2013

News briefs from Alimera on Iluvien and Xencor on Xtend; Galapagos milestone and acquisition

17 January 2013

News briefs from Genmab/Kyowa Hakko; Alimera/Quintiles; Novo Nordisk; Astellas; Sandoz

5 December 2012

NICE rejects Alimera's Iluvien for DMO in draft guidance

8 August 2012

Alimera's Iluvien approved in France for diabetic macular edema

19 July 2012

Alimera's Iluvien approved in Portugal

6 June 2012

Another FDA rejection for Alimera’s DME drug Iluvien

14 November 2011

Alimera resubmits eye drug Iluvien to US regulator

17 May 2011

US FDA approves Novartis’ Amturnide for BP and Watson’s chewable oral contraceptive, but delays Alimera’s Iluvien

24 December 2010

Showing 1-9 of 9 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS